Gilead Pays $1.3B for Oral IL-23 Peptide in IBD Race
Gilead is buying global rights to an oral IL-23 receptor peptide from PepStar, aiming to compete in inflammatory bowel disease and psoriasis.
Digestive disease, hepatology, endoscopy and inflammatory bowel disease.
Digestive disease, hepatology, endoscopy and inflammatory bowel disease.